life scienc diagnost tool
updat model counsyl acquisit rais pt
reiter buy
although ltm sale transact valu compani
ltm revenu steadi top line growth
rang gross margin left us scratch head admittedli
counsyl sharehold could gain upsid choos
transact consider share strateg rational
make lot sens us term enhanc growth
profil high-growth busi establish reimburs
combin product portfolio provid potenti revenu synergi
strengthen competit posit relationship payer
potenti realiz meaning cost synergi counsyl test
menu squar fit mygn oper commerci
infrastructur provid financi guidanc includ counsyl
earn call august transact expect close
take crack incorpor counsyl contribut
model base view conserv assumpt specif
model sizabl moder growth counsyl primari
product expand carrier non-invas prenat screen nt
contempl short-term disrupt integr sale forc
realign etc keep mygn total hereditari cancer revenu
unchang disregard potenti synergi counsyl product
benefit elimin competitor etc long-term
model base segment broad insur coverag
current view signific alter current
competit dynam could upsid faster-than-
expect counsyl integr revenu synergi leverag largest
sale forc women health genet test expand reimburs
reproduct test broader deploy counsyl softwar
capabl believ better posit revenu
re-acceler margin expans next month
page model updat
valuat pt base sale estimate dcf
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
coupl increas risk pass inherit condit cystic
fibrosi spinal muscular atrophi sma etc children order
provid action inform better reproduct health manag
 famili plan earli intervent etc test cover
clinically-action seriou inherit condit high accuraci
believ foresight highest detect rate commerci
avail test market patient screen test posit base
studi publish clinic chemistri may
exhibit clinic util expand carrier screen retrospect
survey at-risk coupl partner carri recess
screen pregnanc
plan ivf
plan chang
diagnosi prenat diagnosi
pndx futur pregnanc
affect
two
miscarri
consid
sever warrant invas
ghiossi et al clinic util expand carrier screen reproduct
behavior at-risk coupl journal genet counsel btig
estim expand carrier screen ec address market
million pregnant women annual exhibit addit
estim carrier screen market increas
test test compound-annual-growth-rate project market
grow test compound-annual-growth-rate long-term project
year take conserv view given carrier screen
once-in-a-lifetim genet test believ time address
market like closer number first child birth
 accord dhh address market could bigger
target patient pre-concept test provid option patient
test partner although could limit partner posit
believ counsyl market leader current expand carrier
screen test estim largest competitor
market rate test access ltm
expand carrier screen rate
labcorp lh rate limit carrier screen
reimburs statu potenti upsid model
reimburs condit cystic fibrosi sma typic
screen tradit carrier screen limit broadli
reimburs believ expand carrier screen could continu gain
traction particularli recent expand guidelin acog
american colleg obstetrician gynecologist recommend
expand carrier screen women regardless ethnic famili
addit new expand carrier screen code expect
establish medicar potenti could provid upsid
foresight asp current model asp foresight
prelud test cell-fre dna test base next gener sequenc
determin common chromosom abnorm syndrom
pregnanc signific clinic evid show cell-fre dna
screen superior methodologist ultrasound serum
screen cell-fre dna screen potenti reduc
tradit invas higher risk procedur amniocentes
chorion villu sampl believ prelud industry-lead low test
estim address market million pregnant women
 annual exhibit also estim market grown
test test compound-annual-growth-rate project
market grow test compound-annual-growth-rate long-term
project year assum address market
high-risk pregnanc pregnanc average-risk
pregnanc nip broadli reimburs today
current multipl larger competitor nip market
includ labcorp acquisit sequenom
roch rog-ch rate acquisit ariosa
neutral acquisit verinata
recent believ larg shift focu provid
instrument consum kit major nip servic provid
instead provid test servic sequenom pool
ip associ non-invas prenat test licens
technolog provid
estim approxim third overal market share
today process unit ltm natera earn call roch
estim approxim market share roch
american associ clinic chemistri scientif meet august
counsyl approxim market share estim
labcorp market share
reimburs statu potenti upsid model
nip current broadli cover high-risk pregnanc
approxim commerci payer cover averag risk pregnant
women addit approxim birth cover
medicaid medicaid live coverag nip
expans average-risk coverag particularli
unitedhealthcar rate aetna aet rate well
medicaid provid upsid model expans potenti especi
driven potenti stronger endors nip pregnanc
acog profession guidelin addit new categori
code detect microdelet clinic lab fee
schedul expand coverag privat payer could provid upsid
prelud asp minimum off-set potenti downward pressur
asp average-risk live cover current model
asp prelud
revenu estim y/i includ
month revenu contribut counsyl ep estim
unchang neutral impact counsyl integr
revenu estim y/i includ
counsyl revenu ep estim y/i vs
prior includ accret counsyl integr
exhibit btig revenu model
note assum counsyl transact financ use common stock issuanc
share balanc evenli split cash hand revolv credit facil
million hereditari cancergenesightvectra daprolarisendopredictcounsyl foresightcounsyl preludemypath melanomaoth mdxpv termin valu aenterpris valu adiscountdcfperpetu growth rate perpetu growth rate net debttot equiti valueequ valu per
fiscal year end jun million except per share diagnost test pre-asc diagnost test clinic servic revenu pre-asc molecular diagnost pharmaceut clinic servic profit molecular diagnost test pre-asc profit molecular diagnost profit pharmaceut clinic gross profit non-gaap pre-asc gross profit sg pre-asc incom incom tax provis incom analysismolecular diagnost test gross margin pre-asc diagnost test gross clinic servic gross margin non-gaap pre-asc gross margin non-gaap pre-asc non-gaap pre-asc margin rate marg growthmolecular diagnost test pre-asc diagnost test revenu pre-asc margin molecular diagnost test pre-asc bpsgross margin molecular diagnost bpstotal gross margin non-gaap pre-asc bpstotal gross margin bpsoper margin bpsep compani report btig
btig cover compani mention report
appendix analyst certif import disclosur
